Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

155.28 +3.47 (+2.29%)
Streaming Delayed Price Updated: 11:49 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
News headline image
Ending HIV-Related Stigma in the Southern United States: Gina's Story
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
What World Cancer Day Means to Me
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Living Well With Hepatitis B: Lai's Journey
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Sciences Named a Best Place to Work for LGBTQ+ Equality in 2022
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Inside the Innovation: Pharmaceutical Development and Manufacturing Leaders Share Experiences
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
From Gilead Sciences, Inc.
Via Business Wire
News headline image
HIV in the Time of COVID-19: The Case for Investment
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Improving HIV Care With Telehealth
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine
From Gilead Sciences Inc.
Via Business Wire
News headline image
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Policy Papers Show Pandemic's Impact on HIV Prevention and Care
SOURCE: Gilead Sciences 
Via 3BL Media
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s... 
Via FinancialNewsMedia
News headline image
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Former Clinician Alain Chan Finds Opportunity to Expand Impact, Develop Personally and Professionally
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Developing Future Social Justice Leaders at Tougaloo College
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead's Rohini Mehtani, Ph.D. Reflects on The Importance of ASH21
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Russian Foundation Provides Career Guidance for Teens Living With HIV
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and Breast Cancer Awareness Month
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the... 
Via FinancialNewsMedia
News headline image
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.